Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Details 1)

Discontinued Operations (Details 1)	12 Months Ended
Discontinued Operations (Details 1)	Aug. 31, 2021 USD ($)
Discontinued Operations
Revenues	$ 3,000
Operating Expenses	(25,000)
Net income	$ (22,000)

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details